GMAB vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GMAB presents a conflicted profile with a stable Piotroski F-Score of 4/9 and a current price ($28.28) trading at a significant premium to its Graham Number ($18.13) and Intrinsic Value ($10.78). While the company maintains elite gross margins (93.6%) and a low P/E relative to the healthcare sector average, it is plagued by a severe YoY earnings collapse of -94.4%. The strong Q/Q revenue growth of 42.25% suggests a potential turnaround, but the bearish technical trend and poor long-term price performance (5Y Change -15.8%) warrant caution.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GMAB vs LLY: Head-to-Head Comparison
This page compares Genmab A/S (GMAB) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.